AdaptHealth Corp. (AHCO) SEC Filings & Earnings Calls
EquiReason read 16 AdaptHealth Corp. SEC filings in the last 12 months. Latest: 8-K on 2026-09-08 — AdaptHealth appointed Harriss Currie as CFO, effective Sept 9, 2026, replacing Jason Clemens who will assist transition through Oct 1, 2026..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 820.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
8 Sep 20268-K · 5.02, 7.01AdaptHealth appointed Harriss Currie as CFO, effective Sept 9, 2026, replacing Jason Clemens who will assist transition through Oct 1, 2026.open
Risks flagged
CFO transition risk, though outgoing CFO assisting through Oct 1
“Jason Clemens, who will assist with the transition through October 1, 2026” · word for word
4 Aug 202610-QAdaptHealth approved a restructuring plan to reduce costs and streamline operations, with expected annual savings of $26.8M, and recognized a $144.2M goodwill impairment.open
Figures in the filing · each found in the filing text
| Net revenue · Q2-2026 | $740M | +13% y/y |
| Net revenue (six months) · H1-2026 | $1.42B | +9% y/y |
| Net loss attributable to AdaptHealth Corp. · Q2-2026 | $-145M | -3538% y/y |
| Adjusted EBITDA · Q2-2026 | $132M | -3% y/y |
| Adjusted EBITDA Margin · Q2-2026 | 17.8% | |
| Goodwill impairment · Q2-2026 | $144M | |
| Cash and cash equivalents · 2026-06-30 | $43M | |
| Diabetes Health sale price · 2026-07 | $235M | |
| Restructuring expected annual savings · FY2027 | $27M | |
| Restructuring total costs · 2026 | $7M |
Risks flagged
Goodwill impairment risk
“AdaptHealth recognized non-cash goodwill impairment charges totaling $144.2 million during the three months ended June 30, 2026.” · word for word
Cybersecurity incident risk
“The Company has confirmed that certain data was exfiltrated from its systems, including patient information and a stored password file associated with insurance billing.” · word for word
Inflationary cost pressure
“Cost of net revenue for the three months ended June 30, 2026 and 2025 was $636.1 million and $521.3 million, respectively, an increase of $114.8 million or 22.0%.”
Margin compression in Wellness at Home
“Adjusted EBITDA from the Wellness at Home segment decreased by $8.8 million or 50.4%.” · word for word
4 Aug 20268-K · 2.02Q2 2026 net revenue $740.3M (+12.7% YoY), organic growth 15.9%, but net loss $145.3M due to $144.2M goodwill impairment, adjusted EBITDA $132.0M (-3.2% YoY). Guidance cut: FY26 adjusted EBITDA lowered to $490-520M from $680-730M, citing Wesearningsopen
Figures in the filing · each found in the filing text
| Net revenue · Q2-2026 | $740M | +13% y/y |
| Organic revenue growth · Q2-2026 | 15.9% | |
| Net loss attributable to AdaptHealth Corp. · Q2-2026 | $-145M | -3560% y/y |
| Adjusted EBITDA · Q2-2026 | $132M | -3% y/y |
| Cash flow from operations (YTD) · H1-2026 | $239M | -7% y/y |
| Free cash flow (YTD) · H1-2026 | $-48M | -166% y/y |
| Registered myAPP users · 2026-06-30 | 512,000 | |
| Goodwill impairment · Q2-2026 | $144M |
Guidance
FY26 revenue $2.85-2.89B (prior not stated); FY26 adjusted EBITDA $490-520M from $680-730M; FY26 free cash flow $80-120M
FY26 guidance cut significantly due to West Coast contract complexity, manufacturer price increase, and Diabetes Health divestiture overhead retention.
Risks flagged
Margin pressure from West Coast capitated contract complexity and manufacturer price increase, leading to significant guidance cut.
“Guidance cut includes $55M impact from West Coast contract and $30M from manufacturer price increase.”
Goodwill impairment of $144.2M indicates potential overpayment for past acquisitions.
“Net loss of $145.3M largely resulting from a $144.2M pre-tax write down of goodwill.”
Negative free cash flow YTD 2026 raises liquidity concerns despite strong revenue growth.
“Free cash flow was negative $48.4 million year-to-date 2026.” · word for word
Corporate overhead retention from Diabetes Health divestiture ($60M) will continue to pressure margins.
“Revised guidance includes $100M impact from Diabetes Health divestiture, including $60M of previously allocated corporate overhead.”
20 Jul 20268-K · 1.01AdaptHealth Corp. sells its diabetes medical device business to Cardinal Health for $235M cash, exiting the diabetes segment.being acquiredopen
Figures in the filing · each found in the filing text
| Purchase price for Diabetes Health business · Diabetes Health · Q3-2026 | $235M | |
| Escrow for post-closing adjustments · Q3-2026 | $8M | |
| Escrow for indemnification · Q3-2026 | $19M | |
| Termination fee payable by Purchaser · Q3-2026 | $9M |
Risks flagged
Transaction subject to regulatory approvals including HSR and other competition laws.
“Closing conditions include expiration or termination of HSR waiting period and consents from other governmental authorities.”
Employee retention risk: at least 80% of offered employees must accept employment.
“Closing condition: acceptance of offers of employment by at least 80% of the offered employees and a specified key employee.”
Material adverse effect clause could allow purchaser to walk away.
“Closing condition: absence of a material adverse effect on the Business since the date of the Purchase Agreement.”
7 Jul 20268-K · 7.01AdaptHealth LLC announces redemption of $325M 6.125% Senior Notes due 2028, funded by a delayed draw term loan borrowing.open
Risks flagged
Redemption conditioned on new borrowing; if condition fails, redemption may be delayed or cancelled.
“The Redemption will be conditioned upon receipt by the Issuer or any of its subsidiaries of the net proceeds of a borrowing under its existing delayed draw term loan facility” · word for word
2 Jul 20268-KClear material cybersecurity incident disclosure with specific details on data exfiltration, attack vector, and ongoing investigation. High confidence due to explicit materiality determination.open
Risks flagged
Patient PII/PHI exfiltrated, potential regulatory fines and lawsuits.
“Data affected includes passwords associated with insurance billing and certain personally identifiable information and protected health information of patients.” · word for word
Social engineering attack on third-party contractor indicates supply chain vulnerability.
“Incident was the result of a successful social engineering attack that compromised a user session associated with a third-party contractor.” · word for word
Full scope of affected data not yet determined, potential for further negative disclosures.
“Full scope of affected data sets has not yet been determined, and specific information regarding the volume of data at issue is not yet available.” · word for word
Reputational damage and potential patient churn.
“Possible effects on patients, counterparties and the Company’s reputation.” · word for word
5 May 202610-QNet revenue $820M (+5% y/y); Adjusted EBITDA $121M (-5% y/y); Adjusted EBITDA Margin 14.8open
Figures in the filing · each found in the filing text
| Net revenue · Q1-2026 | $820M | +5% y/y |
| Adjusted EBITDA · Q1-2026 | $121M | -5% y/y |
| Adjusted EBITDA Margin · Q1-2026 | 14.8% | |
| Organic revenue growth · Q1-2026 | 9.1% | |
| Cash and cash equivalents · 2026-03-31 | $48M | |
| Sleep Health segment revenue · Sleep Health · Q1-2026 | $358M | +13% y/y |
| Respiratory Health segment revenue · Respiratory Health · Q1-2026 | $178M | +8% y/y |
| Diabetes Health segment revenue · Diabetes Health · Q1-2026 | $142M | +2% y/y |
| Wellness at Home segment revenue · Wellness at Home · Q1-2026 | $141M | -10% y/y |
| Sleep Health segment Adjusted EBITDA · Sleep Health · Q1-2026 | $63M | -2% y/y |
Risks flagged
Inflationary cost pressure on margins
“Cost of net revenue increased by $50.9 million or 7.7%.”
Negative free cash flow due to capex
“Free cash flow was negative $27.5 million and negative $0.1 million for the three months ended March 31, 2026 and 2025, respectively.” · word for word
5 May 20268-K · 2.02, 5.02Released earnings results and quarterly financials; reported the departure of a director or principal officer (CEO/CFO change)earningsopen
Risks flagged
COO termination may indicate operational issues.
“terminated the employment of Toby Scott Barnhart, the Company’s Chief Operating Officer.” · word for word
28 Apr 2026DEF 14ANet Revenue $3.24B (-0% y/y); Adjusted EBITDA $617M (-10% y/y); Free Cash Flow $219M (-7% y/y)open
Figures in the filing · each found in the filing text
| Net Revenue · FY2025 | $3.24B | -1% y/y |
| Adjusted EBITDA · FY2025 | $617M | -11% y/y |
| Free Cash Flow · FY2025 | $219M | -7% y/y |
| Cash Flow from Operations · FY2025 | $602M | +11% y/y |
| Net Income (Loss) · FY2025 | $-71M | |
| Goodwill Impairment · FY2025 | $128M | |
| Cash and Equivalents · FY2025 | $106M | -3% y/y |
| Total Goodwill · FY2025 | $2.50B | |
| 2024 Term Loan Outstanding · FY2025 | $315M | -43% y/y |
| Senior Notes Outstanding · FY2025 | $1.44B |
Risks flagged
Goodwill Impairment Risk
“AdaptHealth had $2.5 billion of goodwill recorded on its Consolidated Balance Sheets at December 31, 2025. The impairment test indicated that the estimated fair value of the Company's Diabetes Health reporting unit was less than its carrying value, and as such, AdaptHealth recognized a non-cash goodwill impairment charge of $128.0 million during the year end”
Litigation and Regulatory Risk
“On October 24, 2023, Allegheny County Employees’ Retirement System filed a purported class action complaint... The proposed settlement is expected to be funded as follows: (i) $34.0 million of cash from the Company’s insurance carriers and (ii) $1.0 million of cash from the Company.”
Debt Covenant Compliance Risk
“AdaptHealth’s current indebtedness contain restrictive covenants and require AdaptHealth to maintain or satisfy specified coverage tests. These restrictions and financial and operating covenants include, among other things, requirements with respect to total leverage ratios and an interest charge coverage ratio.”
Reimbursement and Regulatory Risk
“On July 29, 2024, the U.S. Attorney’s Office for the District of South Carolina issued a civil investigative demand to the Company pursuant to the FCA regarding whether the Company submitted false claims in violation of the FCA related to its billing of, and reimbursements from, federal health care programs for humidifiers that are integrated with PAP device”
Diabetes Health Reporting Unit Risk
“The impairment test indicated that the estimated fair value of the Company's Diabetes Health reporting unit was less than its carrying value, and as such, AdaptHealth recognized a non-cash goodwill impairment charge of $128.0 million during the year ended December 31, 2025.”
13 Apr 20268-K · 1.01, 1.02, 2.03, 7.01AdaptHealth LLC entered a new $1.1B credit agreement ($450M revolver, $325M initial term loan, $325M delayed draw term loan) to refinance existing debt and for general corporate purposes, including acquisitions.open
Figures in the filing · each found in the filing text
| Revolving loan commitments | $450M | |
| Initial term loans | $325M | |
| Delayed draw term loan commitments | $325M |
Risks flagged
Increased leverage with financial covenants; potential default risk if not met.
“Consolidated Total Leverage Ratio ... shall not be greater than 3.50 to 1.00”
12 Mar 2026SC 13D/AOne Equity Partners files Amendment No. 4 to Schedule 13D, reporting 11.7% beneficial ownership in AdaptHealth Corp. and recent market purchases.open
Figures in the filing · each found in the filing text
| Beneficial Ownership · 2026-03-10 | 15,864,871 | |
| Beneficial Ownership Percent · 2026-03-10 | 11.7% |
12 Mar 2026SC 13D/AOne Equity Partners files Amendment No. 4 to Schedule 13D, reporting 11.7% beneficial ownership in AdaptHealth Corp. and recent market purchases.open
Figures in the filing · each found in the filing text
| Beneficial Ownership · 2026-03-10 | 15,864,871 | |
| Beneficial Ownership Percent · 2026-03-10 | 11.7% |
24 Feb 202610-KFree cash flow $219M (-7% y/y); Operating cash flow $602M (+11% y/y); Cash and cash equivalents $106M (-3% y/y)open
Figures in the filing · each found in the filing text
| Free cash flow · FY2025 | $219M | -7% y/y |
| Operating cash flow · FY2025 | $602M | +11% y/y |
| Cash and cash equivalents · 2025-12-31 | $106M | -3% y/y |
| Goodwill impairment charge · Diabetes Health · FY2025 | $128M | |
| Working capital · 2025-12-31 | $17M | -91% y/y |
| Term loan outstanding · 2025-12-31 | $315M | -43% y/y |
| Senior notes outstanding · 2025-12-31 | $1.44B | |
| Equipment and other fixed asset purchases · FY2025 | $382M | +25% y/y |
Risks flagged
Goodwill impairment risk
“the excess of the estimated fair value of the Wellness at Home reporting unit over its carrying value was less than 10%, and the excess of the estimated fair value of the Respiratory Health reporting unit over its carrying value was less than 20%.” · word for word
Litigation and regulatory risk
“On July 29, 2024, the U.S. Attorney’s Office for the District of South Carolina issued a civil investigative demand... On March 8, 2025, the U.S. Attorney’s Office for the Eastern District of Pennsylvania issued a civil investigative demand” · word for word
Leverage and debt covenant risk
“AdaptHealth may not be able to generate sufficient cash flow to cover required payments or comply with financial and operating covenants under its long-term debt and long-term operating leases.” · word for word
Reimbursement risk
“The estimated implicit price concession requires significant judgment as it involves the complexity of third-party billing arrangements, contractual terms and the uncertainty of reimbursement amounts.” · word for word
24 Feb 20268-K · 2.02Net revenue $3.24B (-0% y/y); Organic revenue growth 1.7; Net loss attributable to AdaptHealth Corp. $71M; Guidance: FY2026 guidance providedearningsopen
Figures in the filing · each found in the filing text
| Net revenue · FY2025 | $3.24B | -1% y/y |
| Organic revenue growth · FY2025 | 1.7% | |
| Net loss attributable to AdaptHealth Corp. · FY2025 | $71M | |
| Adjusted EBITDA · FY2025 | $617M | -11% y/y |
| Cash flow from operations · FY2025 | $602M | |
| Free cash flow · FY2025 | $219M | |
| Q4 net revenue · Q4-2025 | $846M | -1% y/y |
| Q4 net loss attributable to AdaptHealth Corp. · Q4-2025 | $103M | |
| Q4 adjusted EBITDA · Q4-2025 | $163M | -19% y/y |
| Q4 cash flow from operations · Q4-2025 | $183M |
Guidance
FY2026 guidance provided
FY2026 guidance provided; management optimistic about strong financial performance.
Risks flagged
Goodwill impairment of $128M and legal settlement impacted net loss.
“non-cash goodwill impairment charge of $128.0 million” · word for word
4 Nov 20258-K · 2.02Net revenue $820M (+2% y/y); Net income attributable to AdaptHealth Corp. $24M (+7% y/y); Adjusted EBITDA $170M (+4% y/y); Guidance: FY revenue $3.18B-$3.26B; adjusted EBITDA $642M-$682M; FCF $170M-$190M.earningsopen
Figures in the filing · each found in the filing text
| Net revenue · Q3-2025 | $820M | +2% y/y |
| Net income attributable to AdaptHealth Corp. · Q3-2025 | $25M | +7% y/y |
| Adjusted EBITDA · Q3-2025 | $170M | +4% y/y |
| Cash flow from operations · YTD-2025 | $419M | +7% y/y |
| Free cash flow · YTD-2025 | $140M | -14% y/y |
Guidance
FY revenue $3.18B-$3.26B; adjusted EBITDA $642M-$682M; FCF $170M-$190M.
Maintained FY guidance; strong Q3 with organic growth acceleration; debt reduction progress.
Risks flagged
Free cash flow decline YTD; net leverage still above target.
“Free cash flow $140.1M vs $162.7M; net leverage 2.68x vs target 2.50x.”
4 Nov 202510-QNet revenue $820M (+2% y/y); Net income attributable to AdaptHealth Corp. $25M (+7% y/y); Adjusted EBITDA $170M (+4% y/y)open
Figures in the filing · each found in the filing text
| Net revenue · Q3-2025 | $820M | +2% y/y |
| Net income attributable to AdaptHealth Corp. · Q3-2025 | $25M | +7% y/y |
| Adjusted EBITDA · Q3-2025 | $170M | +4% y/y |
| Adjusted EBITDA Margin · Q3-2025 | 20.7% | |
| Organic revenue growth · Q3-2025 | 5.1% |
Risks flagged
Inflationary Cost Pressure
“Cost of net revenue increased 2.3% YoY; salaries, labor and benefits up 2.9%; patient equipment depreciation up 10.2% due to accelerated depreciation.”
Wellness at Home Segment Decline
“Wellness at Home revenue -16.0% YoY due to dispositions; Adjusted EBITDA -10.8%.”
Payor Mix Shift in Diabetes
“Diabetes Health revenue -2.1% for 9M 2025 due to shift from commercial to government payors.”
AdaptHealth Corp. — questions
- What did AdaptHealth Corp. file recently?
- 16 SEC filings in the last 12 months. Latest: 8-K on 2026-09-08 — AdaptHealth appointed Harriss Currie as CFO, effective Sept 9, 2026, replacing Jason Clemens who will assist transition through Oct 1, 2026.
Every figure on this page comes from AdaptHealth Corp.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.